Patient Buddy App reduced avoidable readmissions in cirrhosis inpatients compared to standard of care.
This randomized clinical trial evaluated the Patient Buddy App (HIT) versus standard of care (SOC) in 464 subjects comprising 232 dyads of cirrhosis inpatients and adult caregivers. The study was conducted across multiple centers including Virginia Commonwealth University, Mayo, and the Department of Veterans Affairs. Follow-up occurred for 30 days post-discharge. Due to COVID-19, an unplanned study redesign required a combined HIT versus SOC comparison. Most dyads reported satisfaction with the app regarding tolerability. Safety data regarding adverse events, serious adverse events, and discontinuations were not reported.
The primary outcome measured avoidable readmissions. Results showed significantly higher rates in the SOC group versus the HIT group with an odds ratio of 2.14 (95% CI 1.01-4.54) and a p-value of 0.04. Absolute numbers indicated 19.8% of patients in the SOC group versus 10.3% in the HIT group experienced avoidable readmissions. When analyzing data after removing pre-COVID HIT+ visits patients, avoidable readmissions remained significantly higher in SOC versus HIT with an odds ratio of 2.41 (95% CI 1.02-5.69) and a p-value of 0.040. Absolute numbers for this subgroup were 19.8% versus 9.3%.
Secondary outcomes assessed all-cause readmissions. Rates were higher in SOC versus HIT with absolute numbers of 48% versus 30% and a p-value of 0.005. The study limitations include the combined comparison group necessitated by the pandemic. Practice relevance is constrained by the specific inpatient cirrhosis population and the unplanned nature of the intervention rollout.